Sportradar Borrow Tightens as Bulls and Bears Square Off Before the Print
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
SRAD heads into its Q3 earnings release on November 3 with the borrow market flashing one of its most constrained readings of the past year, even as short sellers trimmed positions over the last week.
The lending picture is the clearest signal going into the print. Availability has tightened to 9.5%, meaning fewer than one share remains available for every ten already borrowed. That is down sharply from above 80% just five weeks ago, a compression that coincided with the stock's 7% jump on Monday and a 9.4% gain over the past month to $12.87. Cost to borrow has more than doubled over 30 days to 2.07%, reinforcing the message that demand for the short side remains high even as the absolute number of shares short edged lower. Short interest fell roughly 7% over the week to around 15.9 million shares. The ORTEX short score of 72.2 keeps SRAD in the bottom 5% of the universe on that metric, signalling that despite the weekly retreat, aggregate short positioning remains elevated relative to peers.
Options positioning adds a mildly defensive note, though not an alarming one. The put/call ratio of 0.34 is about 1.3 standard deviations above its 20-day average of 0.32, a modest lean toward protection. That reads as selective hedging rather than outright fear: with the PCR still well below its 52-week high of 0.67, bulls are not being crowded out of the options market.
The analyst debate reflects genuine disagreement about Sportradar's near-term trajectory. Multiple firms trimmed price targets in October, with JP Morgan cutting to $13 and Morgan Stanley to $13.50, both barely above or at the current price. Stifel and Canaccord pulled targets lower as well, though both kept Buy ratings. The mean target across the Street is $16.07, implying roughly 25% upside from current levels. Bulls focus on management's reiterated 2026 guidance of €1,557 million to €1,582 million in revenue and at least 21% constant-currency growth, plus the optionality from the Kalshi prediction-market agreement and a $1 billion buyback authorisation. Bears counter that rights cost inflation, FX headwinds, and macroeconomic softness can all erode margins before pricing power materialises, and the August print, which sent the stock down 11% on the day and 8% over the following week, has not been forgotten. The EPS surprise factor score of 11 suggests the company has a weak recent track record of beating estimates, a detail that gives the bear camp additional ammunition.
The ownership structure is notably concentrated. CEO Carsten Koerl holds around 27% of shares, Canada Pension Plan Investment Board holds 23%, and Technology Crossover Management holds a further 10%. Those three parties control roughly 60% of the company between them, a float that is structurally thin and helps explain why borrow availability can tighten so quickly on relatively modest demand shifts. T. Rowe Price trimmed its stake below the 5% threshold in its most recent filing, a quiet exit worth noting. Spruce House, by contrast, filed a fresh 13G in August disclosing a 5.8% position. All stakes are as last disclosed around the 5% threshold, and any holder dropping below that level may not file again.
The print will test whether management can deliver the second-half acceleration it has guided toward, and whether the 11% August sell-off represented a genuine reset or merely the first leg of a longer repricing.
Stocks in this article
See the live data behind this article on ORTEX.
Open SRAD on ORTEX →How this article was generated
- Generated
- 3 Nov 2026, 05:54
- Data as of
- 3 Nov 2026, 04:51
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt Data
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.